Literature DB >> 32407673

Using Chemical Epigenetics to Target Cancer.

Virangika K Wimalasena1, Tingjian Wang2, Logan H Sigua1, Adam D Durbin3, Jun Qi4.   

Abstract

Transcription is epigenetically regulated by the orchestrated function of chromatin-binding proteins that tightly control the expression of master transcription factors, effectors, and supportive housekeeping genes required for establishing and propagating the normal and malignant cell state. Rapid advances in chemical biology and functional genomics have facilitated exploration of targeting epigenetic proteins, yielding effective strategies to target transcription while reducing toxicities to untransformed cells. Here, we review recent developments in conventional active site and allosteric inhibitors, peptidomimetics, and novel proteolysis-targeted chimera (PROTAC) technology that have deepened our understanding of transcriptional processes and led to promising preclinical compounds for therapeutic translation, particularly in cancer.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PROTAC; chromatin; degrader; epigenetics; inhibitor; peptidomimetic; transcription

Mesh:

Substances:

Year:  2020        PMID: 32407673      PMCID: PMC8033568          DOI: 10.1016/j.molcel.2020.04.023

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  95 in total

1.  HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases.

Authors:  Gabriela Paroni; Marco Bolis; Adriana Zanetti; Paolo Ubezio; Kristian Helin; Peter Staller; Lars Ole Gerlach; Maddalena Fratelli; Richard M Neve; Mineko Terao; Enrico Garattini
Journal:  Oncogene       Date:  2018-12-11       Impact factor: 9.867

2.  Development of the first small molecule histone deacetylase 6 (HDAC6) degraders.

Authors:  Ka Yang; Yanling Song; Haibo Xie; Hao Wu; Yi-Ting Wu; Eric D Leisten; Weiping Tang
Journal:  Bioorg Med Chem Lett       Date:  2018-05-30       Impact factor: 2.823

3.  Histone Deacetylases Positively Regulate Transcription through the Elongation Machinery.

Authors:  Celeste B Greer; Yoshiaki Tanaka; Yoon Jung Kim; Peng Xie; Michael Q Zhang; In-Hyun Park; Tae Hoon Kim
Journal:  Cell Rep       Date:  2015-11-05       Impact factor: 9.423

4.  An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.

Authors:  Maia Vinogradova; Victor S Gehling; Amy Gustafson; Shilpi Arora; Charles A Tindell; Catherine Wilson; Kaylyn E Williamson; Gulfem D Guler; Pranoti Gangurde; Wanda Manieri; Jennifer Busby; E Megan Flynn; Fei Lan; Hyo-Jin Kim; Shobu Odate; Andrea G Cochran; Yichin Liu; Matthew Wongchenko; Yibin Yang; Tommy K Cheung; Tobias M Maile; Ted Lau; Michael Costa; Ganapati V Hegde; Erica Jackson; Robert Pitti; David Arnott; Christopher Bailey; Steve Bellon; Richard T Cummings; Brian K Albrecht; Jean-Christophe Harmange; James R Kiefer; Patrick Trojer; Marie Classon
Journal:  Nat Chem Biol       Date:  2016-05-23       Impact factor: 15.040

5.  Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.

Authors:  Xun Huang; Juan Yan; Min Zhang; Yafang Wang; Yi Chen; Xuhong Fu; Rongrui Wei; Xing-Ling Zheng; Zhiwei Liu; Xiong Zhang; Hong Yang; Bingbing Hao; Yan-Yan Shen; Yi Su; Xiaoji Cong; Min Huang; Minjia Tan; Jian Ding; Meiyu Geng
Journal:  Cell       Date:  2018-09-13       Impact factor: 41.582

6.  Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.

Authors:  Haikuo Zhang; Jun Qi; Jaime M Reyes; Lewyn Li; Prakash K Rao; Fugen Li; Charles Y Lin; Jennifer A Perry; Matthew A Lawlor; Alexander Federation; Thomas De Raedt; Yvonne Y Li; Yan Liu; Melissa A Duarte; Yanxi Zhang; Grit S Herter-Sprie; Eiki Kikuchi; Julian Carretero; Charles M Perou; Jacob B Reibel; Joshiawa Paulk; Roderick T Bronson; Hideo Watanabe; Christine Fillmore Brainson; Carla F Kim; Peter S Hammerman; Myles Brown; Karen Cichowski; Henry Long; James E Bradner; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2016-06-16       Impact factor: 39.397

7.  Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3.

Authors:  Jark Böttcher; David Dilworth; Ulrich Reiser; Ralph A Neumüller; Michael Schleicher; Mark Petronczki; Markus Zeeb; Nikolai Mischerikow; Abdellah Allali-Hassani; Magdalena M Szewczyk; Fengling Li; Steven Kennedy; Masoud Vedadi; Dalia Barsyte-Lovejoy; Peter J Brown; Kilian V M Huber; Catherine M Rogers; Carrow I Wells; Oleg Fedorov; Klaus Rumpel; Andreas Zoephel; Moriz Mayer; Tobias Wunberg; Dietrich Böse; Stephan Zahn; Heribert Arnhof; Helmut Berger; Christoph Reiser; Alexandra Hörmann; Teresa Krammer; Maja Corcokovic; Bernadette Sharps; Sandra Winkler; Daniela Häring; Xiao-Ling Cockcroft; Julian E Fuchs; Barbara Müllauer; Alexander Weiss-Puxbaum; Thomas Gerstberger; Guido Boehmelt; Christopher R Vakoc; Cheryl H Arrowsmith; Mark Pearson; Darryl B McConnell
Journal:  Nat Chem Biol       Date:  2019-07-08       Impact factor: 16.174

8.  Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors.

Authors:  Jay H Kalin; Muzhou Wu; Andrea V Gomez; Yun Song; Jayanta Das; Dawn Hayward; Nkosi Adejola; Mingxuan Wu; Izabela Panova; Hye Jin Chung; Edward Kim; Holly J Roberts; Justin M Roberts; Polina Prusevich; Jeliazko R Jeliazkov; Shourya S Roy Burman; Louise Fairall; Charles Milano; Abdulkerim Eroglu; Charlotte M Proby; Albena T Dinkova-Kostova; Wayne W Hancock; Jeffrey J Gray; James E Bradner; Sergio Valente; Antonello Mai; Nicole M Anders; Michelle A Rudek; Yong Hu; Byungwoo Ryu; John W R Schwabe; Andrea Mattevi; Rhoda M Alani; Philip A Cole
Journal:  Nat Commun       Date:  2018-01-04       Impact factor: 14.919

9.  Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.

Authors:  Gerard L Brien; David Remillard; Junwei Shi; Matthew L Hemming; Jonathon Chabon; Kieran Wynne; Eugène T Dillon; Gerard Cagney; Guido Van Mierlo; Marijke P Baltissen; Michiel Vermeulen; Jun Qi; Stefan Fröhling; Nathanael S Gray; James E Bradner; Christopher R Vakoc; Scott A Armstrong
Journal:  Elife       Date:  2018-11-15       Impact factor: 8.713

10.  CTCF maintains regulatory homeostasis of cancer pathways.

Authors:  Sarah J Aitken; Ximena Ibarra-Soria; Elissavet Kentepozidou; Paul Flicek; Christine Feig; John C Marioni; Duncan T Odom
Journal:  Genome Biol       Date:  2018-08-07       Impact factor: 13.583

View more
  18 in total

1.  Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma.

Authors:  Hiroto Ohguchi; Paul M C Park; Tingjian Wang; Berkley E Gryder; Daisuke Ogiya; Keiji Kurata; Xiaofeng Zhang; Deyao Li; Chengkui Pei; Takeshi Masuda; Catrine Johansson; Virangika K Wimalasena; Yong Kim; Shinjiro Hino; Shingo Usuki; Yawara Kawano; Mehmet K Samur; Yu-Tzu Tai; Nikhil C Munshi; Masao Matsuoka; Sumio Ohtsuki; Mitsuyoshi Nakao; Takashi Minami; Shannon Lauberth; Javed Khan; Udo Oppermann; Adam D Durbin; Kenneth C Anderson; Teru Hideshima; Jun Qi
Journal:  Cancer Discov       Date:  2021-04-10       Impact factor: 39.397

2.  EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma.

Authors:  Adam D Durbin; Tingjian Wang; Virangika K Wimalasena; Mark W Zimmerman; Deyao Li; Neekesh V Dharia; Luca Mariani; Noha A M Shendy; Stephanie Nance; Anand G Patel; Ying Shao; Maya Mundada; Lily Maxham; Paul M C Park; Logan H Sigua; Ken Morita; Amy Saur Conway; Amanda L Robichaud; Antonio R Perez-Atayde; Melissa J Bikowitz; Taylor R Quinn; Olaf Wiest; John Easton; Ernst Schönbrunn; Martha L Bulyk; Brian J Abraham; Kimberly Stegmaier; A Thomas Look; Jun Qi
Journal:  Cancer Discov       Date:  2022-03-01       Impact factor: 39.397

3.  Development of Dimethylisoxazole-Attached Imidazo[1,2-a]pyridines as Potent and Selective CBP/P300 Inhibitors.

Authors:  Alex Muthengi; Virangika K Wimalasena; Hailemichael O Yosief; Melissa J Bikowitz; Logan H Sigua; Tingjian Wang; Deyao Li; Zied Gaieb; Gagan Dhawan; Shuai Liu; Jon Erickson; Rommie E Amaro; Ernst Schönbrunn; Jun Qi; Wei Zhang
Journal:  J Med Chem       Date:  2021-04-19       Impact factor: 7.446

Review 4.  Small molecule targeting of chromatin writers in cancer.

Authors:  Andrew R Conery; Jennifer L Rocnik; Patrick Trojer
Journal:  Nat Chem Biol       Date:  2021-12-24       Impact factor: 15.040

Review 5.  m6A modification in RNA: biogenesis, functions and roles in gliomas.

Authors:  Yuhao Zhang; Xiuchao Geng; Qiang Li; Jianglong Xu; Yanli Tan; Menglin Xiao; Jia Song; Fulin Liu; Chuan Fang; Hong Wang
Journal:  J Exp Clin Cancer Res       Date:  2020-09-17

6.  GASC1 promotes glioma progression by enhancing NOTCH1 signaling.

Authors:  Zhengzheng Xiao; Xiaoli Yang; Zebin Liu; Zheng Shao; Chaojun Song; Kun Zhang; Xiaobin Wang; Zhengwei Li
Journal:  Mol Med Rep       Date:  2021-03-02       Impact factor: 2.952

7.  Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.

Authors:  Hiroto Ohguchi; Paul M C Park; Tingjian Wang; Berkley E Gryder; Daisuke Ogiya; Keiji Kurata; Xiaofeng Zhang; Deyao Li; Chengkui Pei; Takeshi Masuda; Catrine Johansson; Virangika K Wimalasena; Yong Kim; Shinjiro Hino; Shingo Usuki; Yawara Kawano; Mehmet K Samur; Yu-Tzu Tai; Nikhil C Munshi; Masao Matsuoka; Sumio Ohtsuki; Mitsuyoshi Nakao; Takashi Minami; Shannon Lauberth; Javed Khan; Udo Oppermann; Adam D Durbin; Kenneth C Anderson; Teru Hideshima; Jun Qi
Journal:  Blood Cancer Discov       Date:  2021-04-10

8.  Properly Substituted Cyclic Bis-(2-bromobenzylidene) Compounds Behaved as Dual p300/CARM1 Inhibitors and Induced Apoptosis in Cancer Cells.

Authors:  Rossella Fioravanti; Stefano Tomassi; Elisabetta Di Bello; Annalisa Romanelli; Andrea Maria Plateroti; Rosaria Benedetti; Mariarosaria Conte; Ettore Novellino; Lucia Altucci; Sergio Valente; Antonello Mai
Journal:  Molecules       Date:  2020-07-08       Impact factor: 4.411

Review 9.  The noncanonical role of EZH2 in cancer.

Authors:  Jinhua Huang; Hongwei Gou; Jia Yao; Kaining Yi; Zhigang Jin; Masao Matsuoka; Tiejun Zhao
Journal:  Cancer Sci       Date:  2021-02-24       Impact factor: 6.716

10.  ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency.

Authors:  Zhendong Cao; Krista A Budinich; Hua Huang; Diqiu Ren; Bin Lu; Zhen Zhang; Qingzhou Chen; Yeqiao Zhou; Yu-Han Huang; Fatemeh Alikarami; Molly C Kingsley; Alexandra K Lenard; Aoi Wakabayashi; Eugene Khandros; Will Bailis; Jun Qi; Martin P Carroll; Gerd A Blobel; Robert B Faryabi; Kathrin M Bernt; Shelley L Berger; Junwei Shi
Journal:  Mol Cell       Date:  2021-08-05       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.